August 31, 2009 – 11:45 am
MedImmune is putting its FluMist nasal spray technology to the test against swine flu. FluMist, which got off to a shaky start in the U.S., brought in only $104 million last year, a fraction of what the big global manufacturers have been able to earn with their flu shots. But all those naysayers who scorned the terms of the MedImmune buyout in the face of such weak performance could well be silenced by the rewards available when a pandemic hits. AstraZeneca plans to make 200 million doses of swine flu vaccine by next spring.
February 23, 2009 – 8:20 am
Goal Is to Provide Signs of Possibility Of Adverse Effect By JARED A. FAVOLE Wall Street Journal WASHINGTON The Food and Drug Administration on Friday unveiled a report listing 20 drugs that the agency is investigating for potential side effects, as part of a new policy to warn patients and health-care professionals as early [...]
September 6, 2008 – 8:15 am
Goal Is to Provide Signs of Possibility Of Adverse Effects By JARED A. FAVOLE WSJ.com, September 5, 2008 8:07 p.m. WASHINGTON — The Food and Drug Administration on Friday unveiled a report listing 20 drugs that the agency is investigating for potential side effects, as part of a new policy to warn patients and health-care [...]
BlogoSquare